Table 2.
Patients analyzed in antigen presentation assays.
Disease | Code | Age range* | ERT/SRT |
---|---|---|---|
Fabry | 1F | 51–55 | Yes |
2F | 36–40 | Yes | |
3F | 61–65 | Yes | |
4F | 51–55 | Yes | |
5F | 46–50 | No | |
6F | 36–40 | No | |
7F | 16–20 | No | |
8F | 21–25 | No | |
Gaucher | 1G | 1–5 | Yes |
2G | 11–15 | Yes | |
3G | 26–30 | Yes | |
4G | 11–15 | Yes | |
5G | 51–55 | No | |
6G | 46–50 | Yes | |
7G | 76–80 | Yes | |
8G | 66–70 | Yes | |
9G | 26–30 | No | |
10G | 36–40 | Yes | |
11G | 71–75 | Yes | |
12G | 71–75 | Yes | |
13G | 60–65 | Yes | |
14G | 6–10 | Yes | |
15G | 21–25 | Yes | |
16G | 21–25 | Yes | |
NPC | 1N | 1–5 | Yes |
2N | 16–20 | Yes | |
3N | 16–20 | Yes | |
4N | 6–10 | Yes | |
5N | 21–25 | Yes | |
6N | 26–30 | Yes | |
7N | 31–35 | Yes | |
8N | 11–15 | Yes | |
MPS-VI | 1M | 16–20 | Yes |
2M | 16–20 | Yes | |
3M | 26–30 | Yes | |
4M | 11–15 | Yes | |
5M | 16–20 | Yes | |
6M | 16–20 | Yes | |
7M | 5–10 | Yes |
Patient age was within this interval at the moment of the study.